Ones To Watch News
Refine Search
Biotechnology
Fred Hassan, an industry veteran behind some of the biggest pharma M&A deals in the past two decades, has been named as chairman of Saghmos Therapeutics. 4 October 2023
Biotechnology
UK respiratory disease focussed biotech Synairgen today announced the appointment of Dr Marcin Mankowski as chief medical officer (CMO), effective immediately. 3 October 2023
Pharmaceutical
Despite positive top-line data, Syndax Pharmaceuticals stock has fallen more than a tenth, following an interim analysis from the AUGMENT-101 trial. 3 October 2023
Biotechnology
After 17 years at GSK, John Lepore’s departure from the UK pharma major was announced last week. 3 October 2023
Pharmaceutical
US pharma company PTC Therapeutics has announced a further strategic prioritization and associated reduction in its workforce. 2 October 2023
Biotechnology
Today, Boston, USA-based Clade Therapeutics announced the acquisition of Gadeta, a Netherlands-based cell therapy company developing innovative gamma/delta (g/d) T-cell receptor (TCR)-based immunotherapies for cancer patients. 2 October 2023
Pharmaceutical
Madrigal Pharmaceuticals, a US biopharma pursuing new therapeutics for non-alcoholic steatohepatitis (NASH), has announced the pricing of its underwritten public offering. 2 October 2023
Biosimilars
A Chinese contract development and manufacturing organization (CDMO), Chime Biologics, has announced a strategic cooperation with South Korea’s Kings Pharm. 29 September 2023
Biotechnology
After several delays, the US Food and Drug Administration (FDA) has finally approved Pombiliti (cipaglucosidase alfa-atga) and Opfolda (miglustat) for the treatment of late onset Pompe disease/LOPD. 29 September 2023
Biotechnology
Information from research group GlobalData suggests there is a pressing need for innovation and collaboration in China to address an unmet medical need in Fabry disease. 29 September 2023
Biotechnology
US antibody-drug conjugate (ADC) specialist ImmunoGen (Nasdaq: IMGN) today announced findings from two subset analyses of the Phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55) evaluating the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx). 28 September 2023
Biotechnology
Having been collaborating for a decade, US RNA-targeted drug developer Ionis Pharmaceuticals and Swiss pharm giant Roche have signed a new agreement. 28 September 2023
Biotechnology
Shares of US biotech Gritstone bio leapt almost 31% to $1.57 in pre-market trading on the news it had been awarded a contract by the Biomedical Advanced Research and Development Authority (BARDA). 28 September 2023
Biotechnology
Seattle, USA-based clinical-stage biopharma Avalyn Pharmaceuticals has announced the closing of an oversubscribed $175 million Series C financing. 28 September 2023
Biotechnology
Sweden-based AAX Biotech revealed that Maria Lisa Knudsen has been appointed as chief executive of the company. 28 September 2023
Biotechnology
CRISPR genome-editing biopharma company Caribou Biosciences (Nasdaq: CRBU) dipped 3% to $4.76, after it revealed it has received notice from a unit of AbbVie (NYSE: ABBV) revealing that the US pharma major has elected to terminate the collaboration and license agreement, first signed in February 2021. 27 September 2023
Biotechnology
Adding to recent big-bucks deals with Merck & Co and Boehringer Ingelheim, Ginkgo Bioworks has now signed a collaboration deal with US pharma giant Pfizer focused on the discovery of RNA-based drug candidates. 27 September 2023
Biotechnology
Italy-based Alfasigma has reached an agreement to acquire US biopharma Intercept Pharmaceuticals. 27 September 2023
Biotechnology
UK clinical-stage biotech PureTech Health today announced the appointment of Robert Lyne as chief portfolio officer. 27 September 2023
Biotechnology
Swedish biotech Biosergen saw its shares close down 14.4% at 1.37 kronor yesterday after it revealed a co-development and licensing deal with Indian drugmaker Alkem Laboratories for BSG005, an innovative polyene macrolide, through Phase II and phase III trials for sale in the Indian market. 27 September 2023
Biotechnology
BioAge Labs today announced a multi-year research collaboration with Swiss pharma giant Novartis, with the news pushing the US biotech’s shares up 6.1% to $4.35 by early afternoon. 18 December 2024
Pharmaceutical
Marking its second deal this month alone, Novo Nordisk has entered into a multi-year collaboration with Massachusetts, USA-based Photys Therapeutics to develop novel proximity-based therapeutics for a cardiometabolic disease target. 18 December 2024
Biotechnology
Cara Therapeutics and Tvardi Therapeutics have announced a definitive agreement to merge, creating a new entity under the Tvardi name. 18 December 2024
Pharmaceutical
SiteOne Therapeutics has announced the completion of a $100 million series C financing, led by Novo Holdings, with participation from OrbiMed, Wellington Management, Mission BioCapital, and others. 18 December 2024
Biotechnology
Flagship Pioneering-founded genome engineering biotech Tessera Therapeutics today announced an investment of up to $50 million from the Bill & Melinda Gates Foundation to develop curative, globally accessible in vivo genetic therapies for sickle cell disease. 18 December 2024
Biotechnology
San Francisco-based Indapta Therapeutics, a privately held start-up developing next-generation cell therapies, has raised $22.5 million in a new financing round. The firm raised over $50 million in series A funding in 2022. 18 December 2024
Biotechnology
French CNS specialist Theranexus saw its shares leap more than 34% to 0.65 euros as it revealed a license and supply agreement with Exeltis to commercialize TX01, its novel formulation of a compound already approved in the indication for the treatment of rare neurological diseases. 18 December 2024
Biotechnology
Shares in US biopharma Viridian Therapeutics shot up by 21% on Monday. 17 December 2024
Biotechnology
US antivirals giant Gilead Sciences today revealed it has entered into a strategic collaboration to discover and develop novel, small molecule therapies across multiple targets with Californian biotech Terray Therapeutics. 17 December 2024
Pharmaceutical
Swedish biotech company Inify Laboratories has raised approximately 135 million kroner ($12.3 million) through a private placement, supporting a planned expansion into the UK. 16 December 2024
Biotechnology
Dewpoint Therapeutics and ConcertAI have announced the first phase of their translational oncology partnership, aligned around the former company's latest drug candidate, DPTX3186. 16 December 2024
Biotechnology
Bicycle Therapeutics, a UK-headquartered pharma company developing a new class of therapeutics based on its proprietary bicyclic peptide technology, closed a third lower on Friday. 16 December 2024
Biotechnology
In a filing with the US financial regulator, German mRNA specialist BioNTech has noted the lifting of a partial clinical hold on its PRESERVE-003 trial. 16 December 2024
Biotechnology
VectorY Therapeutics, a Netherlands-based biotech focused on neurodegenerative diseases, has appointed Jim Scibetta as chief executive officer. 16 December 2024
Biotechnology
Sino-American biotech BeiGene has announced it has entered into a global licensing agreement with China’s CSPC Zhongqi Pharmaceutical Technology for SYH2039, a novel methionine adenosyltransferase 2A (MAT2A)-inhibitor being explored for solid tumors. 13 December 2024
Pharmaceutical
US biotech Corcept Therapeutics has reported positive results from the Phase IV CATALYST study of Korlym (mifepristone) in people with hypercortisolism and difficult-to-control type 2 diabetes. 13 December 2024
Biotechnology
Nine months out from landing an additional $35 million in seed funding, Relation has more news – a big pharma collaboration. The group has announced a $45 million upfront deal, including a $15 million equity investment with UK pharma group GSK. 13 December 2024
Pharmaceutical
UK-based Tenpoint Therapeutics and Seattle’s Visus Therapeutics have announced the completion of their merger to create an entirely new chapter in ophthalmic therapeutic medicines aimed at rejuvenating the aging eye. 12 December 2024
Biotechnology
AI-driven biotech BenevolentAI has announced sweeping changes aimed at refocusing its operations and extending its financial runway into 2027. 12 December 2024
Biotechnology
USA-based Elevation Oncology, an innovative oncology company focused on the discovery and development of selective cancer therapies, has entered into a licensing agreement with Synaffix, part of Swiss out-sourcing major Lonza. 12 December 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
A US biotech company dedicated to creating oral drugs with an emphasis on indications in virology and immunology.
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze